GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » Other Operating Expense

CureVac NV (CureVac NV) Other Operating Expense : $11.44 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Other Operating Expense?

CureVac NV's Other Operating Expense for the three months ended in Mar. 2024 was $0.32 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was $11.44 Mil.

CureVac NV's quarterly Other Operating Expense declined from Sep. 2023 ($3.72 Mil) to Dec. 2023 ($3.31 Mil) and declined from Dec. 2023 ($3.31 Mil) to Mar. 2024 ($0.32 Mil).

CureVac NV's annual Other Operating Expense increased from Dec. 2021 ($-709.27 Mil) to Dec. 2022 ($-18.73 Mil) and increased from Dec. 2022 ($-18.73 Mil) to Dec. 2023 ($14.72 Mil).


CureVac NV Other Operating Expense Historical Data

The historical data trend for CureVac NV's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Other Operating Expense Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial 1.95 -18.20 -709.27 -18.73 14.72

CureVac NV Quarterly Data
Mar19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.43 4.08 3.72 3.31 0.32

CureVac NV Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CureVac NV Other Operating Expense Related Terms

Thank you for viewing the detailed overview of CureVac NV's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV (CureVac NV) Business Description

Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

CureVac NV (CureVac NV) Headlines